Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data
- PMID: 36193854
- PMCID: PMC9896469
- DOI: 10.1093/aje/kwac170
Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data
Abstract
Recombinant zoster vaccine (RZV) (Shingrix; GlaxoSmithKline, Brentford, United Kingdom) is an adjuvanted glycoprotein vaccine that was licensed in 2017 to prevent herpes zoster (shingles) and its complications in older adults. In this prospective, postlicensure Vaccine Safety Datalink study using electronic health records, we sequentially monitored a real-world population of adults aged ≥50 years who received care in multiple US Vaccine Safety Datalink health systems to identify potentially increased risks of 10 prespecified health outcomes, including stroke, anaphylaxis, and Guillain-Barré syndrome (GBS). Among 647,833 RZV doses administered from January 2018 through December 2019, we did not detect a sustained increased risk of any monitored outcome for RZV recipients relative to either historical (2013-2017) recipients of zoster vaccine live, a live attenuated virus vaccine (Zostavax; Merck & Co., Inc., Kenilworth, New Jersey), or contemporary non-RZV vaccine recipients who had an annual well-person visit during the 2018-2019 study period. We confirmed prelicensure trial findings of increased risks of systemic and local reactions following RZV. Our study provides additional reassurance about the overall safety of RZV. Despite a large sample, uncertainty remains regarding potential associations with GBS due to the limited number of confirmed GBS cases that were observed.
Keywords: herpes zoster; managed-care programs; population surveillance; sequential analysis; shingles; vaccine safety; vaccines, combined; zoster vaccine.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9896469/bin/kwac170f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9896469/bin/kwac170f2.gif)
Similar articles
-
Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.Hum Vaccin Immunother. 2024 Dec 31;20(1):2351584. doi: 10.1080/21645515.2024.2351584. Epub 2024 Jun 5. Hum Vaccin Immunother. 2024. PMID: 38838170 Clinical Trial.
-
Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults.Hum Vaccin Immunother. 2022 Nov 30;18(5):2060668. doi: 10.1080/21645515.2022.2060668. Epub 2022 Apr 27. Hum Vaccin Immunother. 2022. PMID: 35476029 Free PMC article.
-
Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.JAMA Intern Med. 2021 Dec 1;181(12):1623-1630. doi: 10.1001/jamainternmed.2021.6227. JAMA Intern Med. 2021. PMID: 34724025 Free PMC article.
-
An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.Drug Saf. 2021 Dec;44(12):1341-1353. doi: 10.1007/s40264-021-01118-3. Epub 2021 Oct 7. Drug Saf. 2021. PMID: 34622421 Free PMC article. Review.
-
A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.Expert Rev Vaccines. 2021 Sep;20(9):1065-1075. doi: 10.1080/14760584.2021.1956906. Epub 2021 Sep 1. Expert Rev Vaccines. 2021. PMID: 34311643 Review.
Cited by
-
Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.Hum Vaccin Immunother. 2023 Dec 15;19(3):2263979. doi: 10.1080/21645515.2023.2263979. Epub 2023 Nov 15. Hum Vaccin Immunother. 2023. PMID: 37967254 Free PMC article. Review.
-
Effects of herpes zoster vaccination and antiviral treatment on the risk of stroke: a systematic review and meta-analysis.Front Neurol. 2023 May 17;14:1176920. doi: 10.3389/fneur.2023.1176920. eCollection 2023. Front Neurol. 2023. PMID: 37265460 Free PMC article.
References
-
- Food and Drug Administration, US Department of Health and Human Services . SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted)[package insert]. Silver Spring, MD: Food and Drug Administration; 2017. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedPr.... Accessed June 29, 2022.
-
- Food and Drug Administration, US Department of Health and Human Services . ZOSTAVAX (Zoster Vaccine Live)[package insert]. Silver Spring, MD: Food and Drug Administration; 2006. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedPr.... Accessed June 29, 2022.
-
- Cunningham AL, Lal H, Kovac M, et al. . Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–1032. - PubMed
-
- Lal H, Cunningham AL, Godeaux O, et al. . Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical